The Applicability of Chromatographic Retention Modeling on Chiral Stationary Phases in Reverse-Phase Mode: A Case Study for Ezetimibe and Its Impurities.
AQbD
DryLab
chiral stationary phase
experimental design
ezetimibe
mechanistic model
related substances
retention modeling
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Nov 2023
08 Nov 2023
Historique:
received:
16
09
2023
revised:
01
11
2023
accepted:
06
11
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Mechanistic modeling is useful for predicting and modulating selectivity even in early chromatographic method development. This approach is also in accordance with current analytical quality using design principles and is highly welcomed by the authorities. The aim of this study was to investigate the separation behavior of two different types of chiral stationary phases (CSPs) for the separation of ezetimibe and its related substances using the mechanistic retention modeling approach offered by the Drylab software (version 4.5) package. Based on the obtained results, both CSPs presented with chemoselectivity towards the impurities of ezetimibe. The cyclodextrin-based CSP displayed a higher separation capacity and was able to separate seven related substances from the active pharmaceutical ingredient, while the cellulose-based column enabled the baseline resolution of six impurities from ezetimibe. Generally, the accuracy of predicted retention times was lower for the polysaccharide CSP, which could indicate the presence of additional secondary interactions between the analytes and the CSP. It was also demonstrated that the combination of mechanistic modeling and an experimental design approach can be applied to method development on CSPs in reverse-phase mode. The applicability of the methods was tested on spiked artificial placebo samples, while intraday and long-term (2 years) method repeatability was also challenged through comparing the obtained retention times and resolution values. The results indicated the excellent robustness of the selected setpoints. Overall, our findings indicate that the chiral columns could offer orthogonal selectivity to traditional reverse-phase columns for the separation of structurally similar compounds.
Identifiants
pubmed: 38003286
pii: ijms242216097
doi: 10.3390/ijms242216097
pmc: PMC10671152
pii:
doi:
Substances chimiques
Ezetimibe
EOR26LQQ24
Polysaccharides
0
Cellulose
9004-34-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Pharm Biomed Anal. 2013 Jun;80:79-88
pubmed: 23528332
Molecules. 2022 Dec 17;27(24):
pubmed: 36558157
J Pharm Biomed Anal. 2017 Feb 5;134:18-26
pubmed: 27871053
J Sep Sci. 2012 Oct;35(19):2529-37
pubmed: 22893517
J Org Chem. 2013 Jul 19;78(14):7048-57
pubmed: 23763523
J Chromatogr A. 2022 Oct 25;1682:463494
pubmed: 36126559
J Pharm Biomed Anal. 2020 Sep 5;188:113412
pubmed: 32590301
J Chromatogr A. 2011 Sep 16;1218(37):6554-60
pubmed: 21802087
J Pharm Biomed Anal. 2022 Nov 30;221:115039
pubmed: 36115204
J Pharm Biomed Anal. 2017 Apr 15;137:60-69
pubmed: 28092856
J Pharm Biomed Anal. 2019 Feb 5;164:395-401
pubmed: 30439666
Chirality. 2014 Mar;26(3):132-5
pubmed: 24453195
J Chromatogr A. 2019 Aug 16;1599:172-179
pubmed: 31005292
J Chromatogr B Biomed Sci Appl. 1997 Feb 7;689(1):123-35
pubmed: 9061488
J Pharm Biomed Anal. 2018 Jul 15;156:379-388
pubmed: 29783113
Chirality. 2013 Sep;25(9):506-13
pubmed: 23775938
J Pharm Biomed Anal. 2017 Oct 25;145:24-32
pubmed: 28646659
Chirality. 2018 Jan;30(1):95-105
pubmed: 29024201
J Pharm Biomed Anal. 2018 Sep 5;158:395-404
pubmed: 29966945
J Pharm Biomed Anal. 2020 Jan 5;177:112851
pubmed: 31499427
J Pharm Biomed Anal. 2016 Jun 5;125:385-93
pubmed: 27131148
J Pharm Biomed Anal. 2017 Nov 30;146:220-225
pubmed: 28886523
Molecules. 2020 Feb 13;25(4):
pubmed: 32069880
Molecules. 2022 Jun 30;27(13):
pubmed: 35807458
Am J Cardiovasc Drugs. 2020 Jun;20(3):239-248
pubmed: 31724105
J Pharm Biomed Anal. 2013 May 5;78-79:65-74
pubmed: 23454599
J Pharm Biomed Anal. 2018 Jun 5;155:116-124
pubmed: 29627728
J Pharm Biomed Anal. 2017 Feb 20;135:8-15
pubmed: 27987393
J Pharm Biomed Anal. 2018 Oct 25;160:336-343
pubmed: 30114612
J Pharm Biomed Anal. 2019 May 10;168:138-147
pubmed: 30807918
J Sep Sci. 2015 Dec;38(24):4173-9
pubmed: 26497314
J Pharm Anal. 2017 Jun;7(3):156-162
pubmed: 29404032
Int J Mol Sci. 2022 Sep 14;23(18):
pubmed: 36142622
J Sep Sci. 2014 May;37(9-10):1083-8
pubmed: 24634398
J Chromatogr A. 2002 Aug 2;965(1-2):175-94
pubmed: 12236524
J Chromatogr A. 2013 Nov 22;1317:167-74
pubmed: 23972462
J Chromatogr A. 1999 Oct 8;858(1):33-43
pubmed: 10544889
Eur J Pharm Sci. 2018 Jun 15;118:208-215
pubmed: 29625210
Pharmaceutics. 2022 May 31;14(6):
pubmed: 35745760
J Pharm Biomed Anal. 2023 Sep 20;234:115495
pubmed: 37343452
Molecules. 2021 Dec 24;27(1):
pubmed: 35011343
J Pharm Biomed Anal. 2021 Sep 5;203:114203
pubmed: 34153936
J Chromatogr A. 2011 Jul 29;1218(30):4869-76
pubmed: 21295310